Across TCGA pan-cancer cohorts, GIMAP1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GIMAP1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher GIMAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GIMAP1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
KIRP, SCLC, and LIHC are the cancer types where GIMAP1 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.